Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
2
|
pubmed:dateCreated |
1988-8-3
|
pubmed:abstractText |
TNF-alpha and IL-1 induce the production of PGE2 from human chondrosarcoma, fibrosarcoma, and carcinoma cell lines. When combined at sub-optimal concentrations, TNF-alpha and IL-1 synergistically stimulate PGE2 production. The synergy of TNF-alpha and IL-1 on the induction of PGE2 is partially neutralized by specific antibodies. In vitro, human rTNF-alpha is directly cytotoxic to several human transplantable tumor cell lines. These include a human carcinoma, human chondrosarcoma, and a human transformed fibroblast cell line. The cytotoxic effect of TNF-alpha was abrogated by a specific, neutralizing, polyclonal antibody. IL-1 had no direct cytotoxic effect on these cell lines; however, IL-1 enhanced the cytotoxic effects of TNF-alpha. The synergy of these two cytokines in the cytotoxic assay was neutralized by the addition of specific neutralizing antibodies.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
AIM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Jul
|
pubmed:issn |
0022-1767
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:day |
15
|
pubmed:volume |
141
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
527-30
|
pubmed:dateRevised |
2004-11-17
|
pubmed:meshHeading |
pubmed-meshheading:3260255-Cell Line,
pubmed-meshheading:3260255-Chondrosarcoma,
pubmed-meshheading:3260255-Cytotoxicity, Immunologic,
pubmed-meshheading:3260255-Dinoprostone,
pubmed-meshheading:3260255-Drug Synergism,
pubmed-meshheading:3260255-Fibrosarcoma,
pubmed-meshheading:3260255-Humans,
pubmed-meshheading:3260255-Interleukin-1,
pubmed-meshheading:3260255-Prostaglandins E,
pubmed-meshheading:3260255-Tumor Cells, Cultured,
pubmed-meshheading:3260255-Tumor Necrosis Factor-alpha
|
pubmed:year |
1988
|
pubmed:articleTitle |
Synergistic and overlapping activities of tumor necrosis factor-alpha and IL-1.
|
pubmed:affiliation |
Department of Immunology, Boehringer Ingelheim Pharamaceuticals, Inc., Ridgefield, CT 06877.
|
pubmed:publicationType |
Journal Article
|